MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To guage many intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Main trial targets were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, whilst one of several exploratory aims https://yoda-176532.webdesign96.com/31439733/not-known-facts-about-imipenem